NanoBio and Porton Biopharma Receive Approval to Advance Next Generation Anthrax Vaccine
NanoBio Corporation today announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by the U.S. National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
NanoBio Receives SBIR Grant For Genital Herpes Vaccine
NanoBio Corporation today announced that it has been awarded a two-year Phase II Small Business Research Innovation (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of an intranasal nanoemulsion (NE) adjuvanted vaccine for the prevention of genital herpes.
NanoBio Awarded U.S. Patent for RSV Vaccine
NanoBio Corporation today announced the issuance of a patent which broadly covers the composition of NanoBio’s intramuscular and intranasal RSV vaccine candidates, combining the company’s innovative nanoemulsion (NE) adjuvant with strain L19 of RSV.
NanoBio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
NanoBio Corporation today announced that the company will present key data at the Mucosal Immunology Course & Symposium Meeting (MICS) in Toronto, demonstrating the advantages of its intranasal nanoemulsion (NE) adjuvant for use in the development of vaccines for pertussis.
NanoBio to Present Data Demonstrating Benefit of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine
NanoBio Corporation will present key data demonstrating the advantages of its nanoemulsion (NE) adjuvant for use in the development of intramuscular vaccines for pandemic influenza and other diseases,at the GTCbio 14th Vaccines Research & Development Conference on June 3, 2016.
NanoBio’s Genital Herpes Vaccine Demonstrates Efficacy in Guinea Pigs as Both a Prophylactic and a Therapeutic Vaccine
NanoBio Corporation today announced that its intranasal nanoemulsion (NE) adjuvanted genital herpes vaccine has demonstrated efficacy in studies conducted in both the prophylactic and the therapeutic guinea pig model. The data was recently presented at the 40th Annual International Herpesvirus Workshop in Boise, ID.
NanoBio to Present Data Demonstrating the Potential for its Intranasal Vaccine to Protect Against Genital Herpes Infection
NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014. The Company’s presentation will highlight the advantages of its nanoemulsion (NE) adjuvant in the development of a prophylactic genital herpes vaccine that induces protection by eliciting both systemic and mucosal immune responses.
NanoBio’s Intranasal Vaccine Demonstrates Robust Protection Against Herpes Simplex-2 Infection
ANN ARBOR, Mich., (April 28, 2014) – NanoBio Corporation today…
NanoBio Awarded Up to $10 Million in NIH Funding to Develop a Pandemic Influenza Vaccine
Additional funding allocated to research nanoemulsion-adjuvanted…
NanoBio to Present Data at ICAAC Supporting the Development of Safe and Effective RSV and Herpes Simplex Virus-2 Vaccines
Pre-clinical data demonstrates the ability of nanoemulsion-adjuvanted…
NanoBio’s Novel NanoStat Technology Demonstrates Significant Effectiveness as Intramuscular Vaccine Adjuvant
New data unveiled at NFID 2013 shows that intramuscular administration…
NanoBio and the U.K. Health Protection Agency Awarded Up to $24 Million to Develop an Intranasal Anthrax Vaccine
ANN ARBOR, Mich. (December 1, 2012) - NanoBio® Corporation announced…
NanoBio Closes $11 Million Series C Financing
Funds Will Support Ongoing Clinical and Preclinical Development…
NanoBio Announces Data Presentation on Its Nanoemulsion Adjuvanted RSV Vaccine at IDWeek 2012
ANN ARBOR, Mich. and SAN DIEGO (October 15, 2012) - NanoBio Corporation…
Announcements and News
- BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
- Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
- BlueWillow Announces Promising Results for Intranasal Covid-19 Booster Vaccine
Contact
BlueWillow Biologics
2311 Green Rd.
Ann Arbor, Mich. 48105
734-302-4000
734-302-9150 fax